A Shurter1, P Genter, D Ouyang, E Ipp. 1. Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, United States.
Abstract
AIMS: In type 2 diabetes, early effects of strict near-normalization of glucose control on macrovascular and microvascular disease are still uncertain. We evaluated the effects of early dramatic improvement in glycemia on retinal disease in poorly controlled diabetes. METHODS: A retrospective, case-control study in public hospital patients with type 2 diabetes, who had annual retinal imaging as part of a case management program or standard diabetes care. Patients included had ≥2 two retinal images ≥1 one year apart, and at least 3 HbA1C measurements. Retinal images were graded using a modified Scottish Diabetic Retinopathy grading scheme. An 'intensive' group (n=34) with HbA1C decrease >1.5% was compared with randomly chosen patients (n=34) with minimal HbA1C changes. RESULTS: Mean HbA1C (±SEM) over two years was similar in intensive (8.5 ± 0.21%) and control groups (8.1 ± 0.28%, p=NS). However, the intensive group had higher baseline HbA1C and a mean maximal decrease of 4.0 ± 0.41% in contrast to the control group (0.2 ± 0.11%). Retinopathy grade progressed +0.7 ± 0.25 units from baseline in the intensive group (p=0.015), a 22.6% worsening. The control group changed minimally from baseline (0.03 ± 0.14 units, p=NS). Change in retinopathy grade was significantly different between groups (p=0.02). More eyes worsened by ≥ 1 retinal grade (p=0.0025) and developed sight-threatening retinopathy (p=0.003) in the intensive group. Visual acuity was unchanged. CONCLUSIONS: Diabetic retinopathy significantly worsened in poorly controlled type 2 diabetes after early intensification of glycemic control and dramatic HbA1C change. Retinal status should be part of risk-factor evaluation in patients likely to experience marked reductions in HbA1C in poorly controlled diabetes.
AIMS: In type 2 diabetes, early effects of strict near-normalization of glucose control on macrovascular and microvascular disease are still uncertain. We evaluated the effects of early dramatic improvement in glycemia on retinal disease in poorly controlled diabetes. METHODS: A retrospective, case-control study in public hospital patients with type 2 diabetes, who had annual retinal imaging as part of a case management program or standard diabetes care. Patients included had ≥2 two retinal images ≥1 one year apart, and at least 3 HbA1C measurements. Retinal images were graded using a modified Scottish Diabetic Retinopathy grading scheme. An 'intensive' group (n=34) with HbA1C decrease >1.5% was compared with randomly chosen patients (n=34) with minimal HbA1C changes. RESULTS: Mean HbA1C (±SEM) over two years was similar in intensive (8.5 ± 0.21%) and control groups (8.1 ± 0.28%, p=NS). However, the intensive group had higher baseline HbA1C and a mean maximal decrease of 4.0 ± 0.41% in contrast to the control group (0.2 ± 0.11%). Retinopathy grade progressed +0.7 ± 0.25 units from baseline in the intensive group (p=0.015), a 22.6% worsening. The control group changed minimally from baseline (0.03 ± 0.14 units, p=NS). Change in retinopathy grade was significantly different between groups (p=0.02). More eyes worsened by ≥ 1 retinal grade (p=0.0025) and developed sight-threatening retinopathy (p=0.003) in the intensive group. Visual acuity was unchanged. CONCLUSIONS:Diabetic retinopathy significantly worsened in poorly controlled type 2 diabetes after early intensification of glycemic control and dramatic HbA1C change. Retinal status should be part of risk-factor evaluation in patients likely to experience marked reductions in HbA1C in poorly controlled diabetes.
Authors: George A Williams; Ingrid U Scott; Julia A Haller; Albert M Maguire; Dennis Marcus; H Richard McDonald Journal: Ophthalmology Date: 2004-05 Impact factor: 12.079
Authors: Julienne K Kirk; Leah V Passmore; Ronny A Bell; K M Venkat Narayan; Ralph B D'Agostino; Thomas A Arcury; Sara A Quandt Journal: Diabetes Care Date: 2007-10-31 Impact factor: 19.112
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Tien Yin Wong; Ronald Klein; F M Amirul Islam; Mary Frances Cotch; Aaron R Folsom; Barbara E K Klein; A Richey Sharrett; Steven Shea Journal: Am J Ophthalmol Date: 2006-03 Impact factor: 5.258
Authors: Athena Philis-Tsimikas; Chris Walker; Lisa Rivard; Gregory Talavera; Joachim O F Reimann; Michelle Salmon; Rachel Araujo Journal: Diabetes Care Date: 2004-01 Impact factor: 19.112
Authors: M Angelyn Bethel; Rafael Diaz; Noelia Castellana; Indranil Bhattacharya; Hertzel C Gerstein; Mark C Lakshmanan Journal: Diabetes Care Date: 2021-01 Impact factor: 19.112
Authors: Enrique O Graue-Hernandez; David Rivera-De-La-Parra; Sergio Hernandez-Jimenez; Carlos A Aguilar-Salinas; David Kershenobich-Stalnikowitz; Aida Jimenez-Corona Journal: BMJ Open Ophthalmol Date: 2020-03-10